Clinical trial NCT00132379: ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer
Official title: An Open-label, Phase I, Dose-escalation Study of ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Carcinoma, Non-Small-Cell Lung
Lead sponsor: Active Biotech AB
Sponsor class: INDUSTRY
First posted: 2005-08-22
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug, in combination with docetaxel (an approved drug for treating non-small cell lung cancer \[NSCLC\]), can be given to patients with NSCLC without causing unacceptable side effects.


Eligibility criteria: Inclusion Criteria:

* Patients with histologically or cytologically confirmed advanced NSCLC who have progressed on first line platin-based therapy or have failed on other treatment regimens or declined standard regimen.
* ECOG performance status 0 or 1.
* Adequate bone marrow function: absolute neutrophil count greater than or equal to 1500/mm3; WBC greater than or equal to 3000/mm3; platelets greater than or equal to 100,000/mm3; and hemoglobin greater than or equal to 10 g/dL.
* Adequate renal function: creatinine less than or equal to 1.5 x upper limit of normal (ULN).
* Adequate hepatic function: bilirubin less than ULN; and SGOT (AST) and SGPT (ALT) to less than 1.5 x ULN concomitant with alkaline phosphatase (ALP) less than 2.5 ULN.

Exclusion Criteria:

* Female patients who are pregnant or nursing or planning to become pregnant during the study. Fertile, sexually active women not willing to practice reliable contraception. Male patients with partners of childbearing potential not using acceptable contraceptive method.
* A serious uncontrolled medical disorder or active infection including unexplained fever (temperature greater than 100.5 degrees Fahrenheit or 38.1 degrees Celsius) that would impair the patient's ability to receive study treatment.
* Any concurrent malignancy, except for the following malignancies that may be included: non-melanoma skin cancer; cervical cancer in situ; ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) of breast; or past history of prostate cancer without clinical evidence of disease (includes patients receiving hormonal therapy).
* History of brain metastases, unless stable for more than 4 weeks, and not requiring steroid therapy and without clinical symptoms of brain metastases.
* Significant symptomatic cardiac disease including history (within past 6 months) or current unstable angina, congestive heart failure, or myocardial infarction; or patients with uncontrolled hypertension, or hypertension requiring treatment with more than 2 drugs.
* History of or current arrhythmias requiring treatment, except for non-specific, asymptomatic ST-T wave changes or extrasystoles.
* Seizure disorder requiring therapy.
* Treatment with beta-blockers, including topical therapy for glaucoma, during the 6-day treatment period (5-day treatment + 1 day in-patient follow-up), and within 5 days before start of ABR-217620 treatment.
* Simultaneous participation in any other investigational drug study or participation in a study less than 4 weeks before start of study treatment.
* Treatment with systemic or inhaled corticosteroids within 2 weeks before start of treatment.
* Treatment with anticoagulants, except when used to maintain the patency of a central venous line.
* Active autoimmune disease requiring therapy or any history of systemic lupus erythematosus or rheumatoid arthritis.
* Concurrent biological response modifiers (within 3 weeks of study entry) except for any type of erythropoetin.
* Chemo/radio/immunotherapy less than 4 weeks (6 weeks for mitomycin C and nitrosoureas) before start of treatment.
* Known allergy or hypersensitivity reactions to aminoglycosides (e.g., kanamycin).
* Known allergy or hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80.
* Previous exposure to murine monoclonal antibody (with human anti-mouse antibody \[HAMA\] titer above detection limit at baseline) or known hypersensitivity to murine proteins.
* Major surgery within 3 weeks.
* Known history of HIV infection.
* Known chronic hepatitis B or C.

Primary outcomes:
measure: Side effect profile (based on blood pressure, body temperature, and laboratory tests)
timeFrame: Day 56 (Day 115 if undergo cycles 3/4)
Secondary outcomes:
measure: Pharmacokinetic parameters
timeFrame: Days 1 and 4 of cycles 1 and 2
measure: Immunological response
timeFrame: Day 56 (Day 115 if undergo cycles 3/4)
measure: Changes in anti-SEA/E-120 levels
timeFrame: Day 56 (Day 115 if undergo cycles 3/4)
measure: Objective response rate
timeFrame: Day 56 (Day 115 if undergo cycles 3/4)
measure: Time to progression and Survival
timeFrame: Followed for up to 1 year
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Fox Chase Cancer Center
state: Pennsylvania
city: Copenhagen
country: Denmark
facility: Onkologisk Klinik, Rigshospitalet
city: St. Petersburg
country: Russian Federation
facility: City Multifield Hospital #2, City Center of Intensive Pulmonology and Thoracic Surgery
city: St. Petersburg
country: Russian Federation
facility: St. Petersburg Pavlov State Medical University
Study officials:
affiliation: Active Biotech AB
name: Suzanne Kilany
role: STUDY_DIRECTOR
References: